Tetraneuron

Tetraneuron is a clinical-stage biotechnology company developing gene therapies for neurodegenerative diseases, with a primary focus on Alzheimer's. Founded in 2012 by Jose M Frade, Lucia Almonacid Olleros, and Cristina Payan Rodriguez, the company is headquartered in Madrid and Valencia, Spain. The scientific team, including co-founder and Scientific Director José M. Frade, possesses extensive experience in neuroscience. The company's core technology centers on the E2F4 protein, which is involved in regulating multiple brain pathways. Tetraneuron is developing treatments designed to restore biological processes affected by the pathogenic phosphorylation of this protein.

The company's main drug candidate, TET-101, is a multifactorial gene therapy for Alzheimer's disease. The approach is considered distinct because it targets a master gene that regulates neuronal homeostasis, and has not shown the toxicity issues that can be associated with such strategies. In addition to its therapeutic pipeline, which also includes candidates for glaucoma and Parkinson's, Tetraneuron is developing an early diagnostic biomarker for Alzheimer's risk. The business operates on a model of advancing its proprietary therapies through preclinical and clinical trials to demonstrate safety and efficacy. Tetraneuron has engaged in a pre-IND meeting with the FDA and has been part of the Johnson & Johnson Innovation - JLABS incubator program, which provides access to a global life science network and entrepreneurial programs. The firm has secured funding through rounds including a Series A, and is backed by investors like JLABS.

Keywords: gene therapy, neurodegenerative diseases, Alzheimer's disease, E2F4 protein, clinical-stage, biotechnology, drug discovery, neuroscience, diagnostic biomarker, JLABS